Use SAH to screen COMT inhibitors for Parkinson’s disease
Deciphering the epigenome
Discover an epigenetics assay portfolio you'll never outgrow
The science of change
Epigenetic mechanisms have been increasingly associated with a broad spectrum of pathologies, from cancer to metabolic diseases, and even psychiatric disorders.
Trigerred by many external environmental factors, the mechanisms can regulate gene transcription. Whether writers, erasers, or readers, epigenetic targets have naturally opened a whole new area for drug discovery amplifying the need for new sensitive and extremely specific tools.
From specific to universal enzymatic assays
Specificity matters when it comes to enzymatic assays. With a number of epigenetic enzymes targeting histone H3 modifications, Cisbio has optimized a full range of highly specific assays, each of which detects a unique mark. Set up your own assay in record time! Methyltransferases, demethylases, and deacetylases have been validated extensively and are already documented here.
When a different substrate is involved, or if no specific probe is available, researchers can run the EPIgeneous methyltransferase assay that quantifies SAH, the by-product of enzymatic methylation. This unique format enables you to investigate all types of methyltransferases/substrates: histones, DNA, proteins, small metabolites, etc.
Reading the genome, closer to regulation
Writer and eraser proteins are just one facet of epigenetic regulators. Readers, such as the BET family, are driving the way the transcription is conducted. They have therefore become pivotal targets for discovery. Cisbio has created a selection of three different assays for those readers based on the same format that covers most of this important binding protein array, with data for each of the 28 validated binding domain configurations.
Your binding domain is not listed? The Cisbio Discovery assay will help you pick the best kit option in a single try.
Methylation in cell
Methylation can also be studied directly in cells. Cisbio has optimized buffers to extract modified histones from the nucleus to investigate specific methylation marks in a cellular context, closer to physiology.
And because compound stimulations are generally long and may impact cell viability, our kits can be associated with the detection of Total histone H3 using the same lysate for assay normalization.
Development of an HTRF assay to measure the binding of the HMT to its in...
Use fluorescence screening assays